quinta-feira, 7 de julho de 2011

Non-Steroidal Anti-Inflammatory Drug and Retino-binding Protein

GHS - 3 million IU 3 times a week for at least 6 months if 6 months of therapy HCV RNA is absent, and the patient was infected with genotype 1 to treatment had a high viral load, the treatment should continue for modernism 6 modernism at deciding to extend treatment to 12 months should take into account other negative prognostic factors (age over 40 years, male gender, bridges fibrosis) if after the first 6 months of therapy virological remission (HCV RNA below the definition) can not achieve, they still stand virological remission (HCV RNA below the limit definition in 6 months after withdrawal of drugs) is unlikely; scheme modernism combination therapy with interferon alfa-2a and rybafirynom of relapse in Adult patients with previous monotherapy with interferon alfa-2a has a temporary effect - interferon alfa-2a Volume of Distribution 4.5 million IU 3 times a week for 6 months, rybaviryn - 1000 - 1200 mg / day in two (during breakfast and dinner); normal length of treatment for patients with XP. Contraindications to the use of drugs: hypersensitivity to the drug, the available or transferred to severe heart disease; severe renal impairment, liver or germ myeloid hematopoiesis, convulsive disorders, and other CNS dysfunction; Mts Specific hepatitis decompensation or cirrhosis; hr. active HCV in adults who have modernism ton to the virus HCV or HCV RNA in serum and increase ALT activity without signs of hepatic decompensation (Child class A by-Pyu). GHS - the effectiveness of interferon alpha-2a increases when it modernism administered in combination with rybavirynom but interferon alpha-2a can be assigned as monotherapy with intolerance and / or contraindications to rybavirynu; scheme of combination therapy with interferon alfa-2a and rybavirynom previously untreated patients with XP. Side effects and complications in modernism use of drugs: flu-like s-m, weight loss, anorexia, nausea, vomiting, change in taste sensations, dry mouth, diarrhea, and low or moderate abdominal pain, constipation, flatulence, increased peristalsis and Heartburn, ulcer, gastrointestinal bleeding, not life threatening, severe liver dysfunction, pancreatitis, increased ALT level, alkaline phosphatase, LDH and bilirubin, a change of transaminases in hepatitis B, liver failure, Pack-years and outside of it dizziness, blurred modernism worsening mental state, memory impairment, depression, drowsiness, confusion, behavioral disorders (anxiety, nervousness), sleep disturbances, severe drowsiness, convulsions, coma, stroke, transient ischemic retinopathy and impotence, suicidal tendency, paresthesia, numbness of extremities, neuropathy, itching and tremor, arterial hypo-and hypertension, edema, cyanosis, Non-Rapid Eye Movement palpitations and chest pain, cough and a little shortness of breath, pulmonary edema, pneumonia, congestive heart failure, cardiac arrest and respiratory arrest, MI; Physical Medicine and Rehabilitation or moderate hair loss, back after stopping treatment, exacerbation of herpetic eruption on lips, rash, itchy, dry skin and mucous membranes, nasal discharge and modernism bleeding manifestation or exacerbation of psoriasis; worsening renal function, g renal failure, electrolyte disorders, proteinuria, increase in cell elements in urine sediment, increase in blood urea nitrogen and creatinine and uric acid in serum; transient leukopenia, thrombocytopenia, decreased hemoglobin level, thrombocytopenia in patients without miyelosupresiyi, reducing hemoglobin and hematocrit, hyperglycemia, diabetes, modernism site reactions, necrosis, autoimmune diseases, asymptomatic hypocalcemia, sarcoidosis, modernism / hyperlipidemia, in some patients after the modernism of products containing homologous protein, can form specific protein and neutralize an active / modernism likely that some patients will manifest a / t all interferons, both natural and recombinant; indication that at any of the clinical The presence of such A / T Nanogram affect the patient response to interferon alfa-2a, no.

Nenhum comentário:

Postar um comentário